Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension

Chang Ming Chern, Hung Yi Hsu, Han Hwa Hu, Yen Yu Chen, Li Chi Hsu, A. Ching Chao

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Baroreflex sensitivity (BRS) and heart rate variability (HRV) are potential therapeutic targets. The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension. Thirty subjects with uncomplicated essential hypertension were randomized to receive atenolol 50 mg to 100 mg (n = 15) or losartan 50 mg to 100 mg (N = 15) daily for 6 months. Instantaneous systolic blood pressure (SBP) and heart rate were assessed using servo-controlled infrared finger plethysmography before treatment and at the end of 3 months and 6 months after treatment. The fluctuation in SBP and interpulse interval (IPI) was divided into three specific frequency ranges by fast Fourier transform as high frequency (HF; 0.15 Hz-0.4 Hz), low frequency (LF; 0.04 Hz-0.15 Hz), and very low frequency (VLF; 0.004 Hz-0.04 Hz). The BRS was expressed as (1) SBP-IPI transfer function with its magnitude in the HF and LF ranges and (2) BRS index alpha. The HRV was expressed as total power and power in the LF and HF ranges of interpulse interval. Blood pressure was reduced to a similar extent in both groups. Compared with the baseline, BRS did not improve in both groups at month 3. However, BRS was significantly improved in the losartan group (P < 0.05) but not in the atenolol group at month 6. In addition, BRS was significantly higher in the losartan group than the atenolol group at month 3 and month 6 (P < 0.05). Moreover, heart rate variability was significantly reduced in the atenolol group at month 6 (P < 0.05), but not in the losartan group. The HRV in the losartan group was significantly higher than that in the atenolol group at month 6 (P < 0.05). These findings suggest superior effects of losartan on BRS and HRV than atenolol in uncomplicated essential hypertension, which may be beyond blood pressure reduction/resetting.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 1 2006
Externally publishedYes

Fingerprint

Atenolol
Losartan
Baroreflex
Heart Rate
Blood Pressure
Plethysmography
Essential Hypertension
Fourier Analysis
Fingers
Therapeutics

Keywords

  • Atenolol
  • Baroreflex sensitivity
  • Essential hypertension
  • Heart rate variability
  • Losartan

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. / Chern, Chang Ming; Hsu, Hung Yi; Hu, Han Hwa; Chen, Yen Yu; Hsu, Li Chi; Chao, A. Ching.

In: Journal of Cardiovascular Pharmacology, Vol. 47, No. 2, 01.02.2006, p. 169-174.

Research output: Contribution to journalArticle

Chern, Chang Ming ; Hsu, Hung Yi ; Hu, Han Hwa ; Chen, Yen Yu ; Hsu, Li Chi ; Chao, A. Ching. / Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. In: Journal of Cardiovascular Pharmacology. 2006 ; Vol. 47, No. 2. pp. 169-174.
@article{2af898b057cd497083caa6e0ffbaac10,
title = "Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension",
abstract = "Baroreflex sensitivity (BRS) and heart rate variability (HRV) are potential therapeutic targets. The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension. Thirty subjects with uncomplicated essential hypertension were randomized to receive atenolol 50 mg to 100 mg (n = 15) or losartan 50 mg to 100 mg (N = 15) daily for 6 months. Instantaneous systolic blood pressure (SBP) and heart rate were assessed using servo-controlled infrared finger plethysmography before treatment and at the end of 3 months and 6 months after treatment. The fluctuation in SBP and interpulse interval (IPI) was divided into three specific frequency ranges by fast Fourier transform as high frequency (HF; 0.15 Hz-0.4 Hz), low frequency (LF; 0.04 Hz-0.15 Hz), and very low frequency (VLF; 0.004 Hz-0.04 Hz). The BRS was expressed as (1) SBP-IPI transfer function with its magnitude in the HF and LF ranges and (2) BRS index alpha. The HRV was expressed as total power and power in the LF and HF ranges of interpulse interval. Blood pressure was reduced to a similar extent in both groups. Compared with the baseline, BRS did not improve in both groups at month 3. However, BRS was significantly improved in the losartan group (P < 0.05) but not in the atenolol group at month 6. In addition, BRS was significantly higher in the losartan group than the atenolol group at month 3 and month 6 (P < 0.05). Moreover, heart rate variability was significantly reduced in the atenolol group at month 6 (P < 0.05), but not in the losartan group. The HRV in the losartan group was significantly higher than that in the atenolol group at month 6 (P < 0.05). These findings suggest superior effects of losartan on BRS and HRV than atenolol in uncomplicated essential hypertension, which may be beyond blood pressure reduction/resetting.",
keywords = "Atenolol, Baroreflex sensitivity, Essential hypertension, Heart rate variability, Losartan",
author = "Chern, {Chang Ming} and Hsu, {Hung Yi} and Hu, {Han Hwa} and Chen, {Yen Yu} and Hsu, {Li Chi} and Chao, {A. Ching}",
year = "2006",
month = "2",
day = "1",
doi = "10.1097/01.fjc.0000199225.17928.f5",
language = "English",
volume = "47",
pages = "169--174",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension

AU - Chern, Chang Ming

AU - Hsu, Hung Yi

AU - Hu, Han Hwa

AU - Chen, Yen Yu

AU - Hsu, Li Chi

AU - Chao, A. Ching

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Baroreflex sensitivity (BRS) and heart rate variability (HRV) are potential therapeutic targets. The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension. Thirty subjects with uncomplicated essential hypertension were randomized to receive atenolol 50 mg to 100 mg (n = 15) or losartan 50 mg to 100 mg (N = 15) daily for 6 months. Instantaneous systolic blood pressure (SBP) and heart rate were assessed using servo-controlled infrared finger plethysmography before treatment and at the end of 3 months and 6 months after treatment. The fluctuation in SBP and interpulse interval (IPI) was divided into three specific frequency ranges by fast Fourier transform as high frequency (HF; 0.15 Hz-0.4 Hz), low frequency (LF; 0.04 Hz-0.15 Hz), and very low frequency (VLF; 0.004 Hz-0.04 Hz). The BRS was expressed as (1) SBP-IPI transfer function with its magnitude in the HF and LF ranges and (2) BRS index alpha. The HRV was expressed as total power and power in the LF and HF ranges of interpulse interval. Blood pressure was reduced to a similar extent in both groups. Compared with the baseline, BRS did not improve in both groups at month 3. However, BRS was significantly improved in the losartan group (P < 0.05) but not in the atenolol group at month 6. In addition, BRS was significantly higher in the losartan group than the atenolol group at month 3 and month 6 (P < 0.05). Moreover, heart rate variability was significantly reduced in the atenolol group at month 6 (P < 0.05), but not in the losartan group. The HRV in the losartan group was significantly higher than that in the atenolol group at month 6 (P < 0.05). These findings suggest superior effects of losartan on BRS and HRV than atenolol in uncomplicated essential hypertension, which may be beyond blood pressure reduction/resetting.

AB - Baroreflex sensitivity (BRS) and heart rate variability (HRV) are potential therapeutic targets. The present study was conducted to assess changes in BRS and HRV after monotherapy with losartan versus that of atenolol in uncomplicated essential hypertension. Thirty subjects with uncomplicated essential hypertension were randomized to receive atenolol 50 mg to 100 mg (n = 15) or losartan 50 mg to 100 mg (N = 15) daily for 6 months. Instantaneous systolic blood pressure (SBP) and heart rate were assessed using servo-controlled infrared finger plethysmography before treatment and at the end of 3 months and 6 months after treatment. The fluctuation in SBP and interpulse interval (IPI) was divided into three specific frequency ranges by fast Fourier transform as high frequency (HF; 0.15 Hz-0.4 Hz), low frequency (LF; 0.04 Hz-0.15 Hz), and very low frequency (VLF; 0.004 Hz-0.04 Hz). The BRS was expressed as (1) SBP-IPI transfer function with its magnitude in the HF and LF ranges and (2) BRS index alpha. The HRV was expressed as total power and power in the LF and HF ranges of interpulse interval. Blood pressure was reduced to a similar extent in both groups. Compared with the baseline, BRS did not improve in both groups at month 3. However, BRS was significantly improved in the losartan group (P < 0.05) but not in the atenolol group at month 6. In addition, BRS was significantly higher in the losartan group than the atenolol group at month 3 and month 6 (P < 0.05). Moreover, heart rate variability was significantly reduced in the atenolol group at month 6 (P < 0.05), but not in the losartan group. The HRV in the losartan group was significantly higher than that in the atenolol group at month 6 (P < 0.05). These findings suggest superior effects of losartan on BRS and HRV than atenolol in uncomplicated essential hypertension, which may be beyond blood pressure reduction/resetting.

KW - Atenolol

KW - Baroreflex sensitivity

KW - Essential hypertension

KW - Heart rate variability

KW - Losartan

UR - http://www.scopus.com/inward/record.url?scp=33746413031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746413031&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000199225.17928.f5

DO - 10.1097/01.fjc.0000199225.17928.f5

M3 - Article

VL - 47

SP - 169

EP - 174

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -